Glynn, David http://orcid.org/0000-0002-0989-1984
Bliss, Judith
Brunt, Adrian Murray
Coles, Charlotte E.
Wheatley, Duncan
Haviland, Joanne S.
Kirby, Anna M.
Longo, Francesco
Faria, Rita http://orcid.org/0000-0003-3410-1435
Yarnold, John R.
Griffin, Susan
Funding for this research was provided by:
National Institute for Health Research (09/01/47)
The institute of Cancer Research (C1491/A6035)
Article History
Received: 20 January 2022
Accepted: 18 October 2022
First Online: 17 November 2022
Declarations
:
: AMB, SG, DG, FL, DW, AK, CEC, JSH, JRY declare no conflicts of interest. Since this study was completed, RF became an employee of Astellas Pharma Europe Ltd. JB declares AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Pfizer, Roche, Novartis (previously GSK), Eli Lilly, Janssen-Cilag and Clovis Oncology. The authors acknowledge indirect conflicts through their funding and affiliations described above and through their involvement with the FAST Forward and IMPORT LOW trials.
: This is a study based on secondary data without primary data collection, and therefore, no ethical approval is required.